Employee Secondary Surges Amidst the Drought for Liquidity

Keegan Hasson
December 19

Historically, private companies have given employees equity incentives as an attractive supplement to cash compensation.  However, employees have only been able to convert that paper wealth to cash through acquisition, IPO, or a secondary sale.  In the past couple of years, liquidity events have tumbled. After a surge of 311 VC-backed IPOs in 2021, there were only 38 in 2022 and even fewer in 2023. Healthcare M&A also decreased by 30% in 2022 and fell again this year. This liquidity “drought” has sent reverberations through the market for talent and has increased the reliance on secondary sales as a liquidity channel for employees.

Take this example:

Companies Y and Z both make healthcare widgets and have similar commercialization trajectories, but Y is one year ahead of Z in its growth curve. In 2021, the CEO of Y was given the choice to go public and pulled the trigger. Early employees happily cashed out. Y’s founder was even able to take some chips off the table.

In 2022, the CEO of Z was given the same choice but stayed private. Fast-forward two years, and the window for IPOs remains shut. The employees of Z are left without traditional forms of liquidity and are seeking the promised fruits for their efforts.

The employees of Z are not alone. Across the larger economy, decision-makers at companies like Z are facing a paradox where employee expectations for liquidity are increasing at the same time as traditional  liquidity events such as IPO or an M&A transaction have dried up. Morgan Stanley at Work recently surveyed 311 private company decision-makers who currently offer an equity plan and discovered that the issue has been pulled into the limelight:

  • 37% of private company decision makers report that their companies are staying private longer than originally planned, and 34% are unsure or questioning next steps.
  • 59% report increased pressure to hold a liquidity event.
  • 73% state that equity, in general, has become more valuable to prospective talent than years before.
  • 93% report that the company’s ability and/or possibility of having a liquidity event is valuable to a prospect’s decision when considering a job offer.

In the absence of IPOs, M&A, SPACs and direct listings, secondary liquidity has become a release valve. Direct secondaries are expected to reach $85 billion of volume in 2023, up from $12 billion in 2012 and $60 billion in 2021. These secondary offerings have traditionally taken on several forms:

  • Tender offer: a structured liquidity event that allows a set of eligible shareholders to sell their shares to an investor, a group of investors or back to the company at a predetermined price.
  • Direct secondary sales: a shareholder in a company sells their shares to another investor.
  • Company sponsored program for shareholders and employees to participate in secondary transactions.

Revelation Partners has 10 years of experience helping companies navigate direct secondaries. If you’re a decision-maker at a private healthcare company dealing with this dilemma, we would be happy to start the dialogue. We have a variety of tools in our kit, from helping structure employee liquidity programs, founder liquidity, angel investor liquidity, and more. In the meantime, we’ve published a few whitepapers to help give you a head start:

Source: Morgan Stanley At Work, Liquidity Trends Report 2023: Perspectives from Private Company Leaders

Disclaimer

The information contained herein is for informational and educational purposes only, does not constitute an offer to sell or the solicitation of an offer to purchase any security, is not presented with a view to providing investment advice with respect to any security, or making any claim as to the past, current or future performance thereof, and Revelation expressly disclaims the use of this document for such purposes. Each recipient should consult its own advisers as to legal, business, tax and other related matters concerning any investment.

Statements contained herein are based on current expectations, estimates, projections, opinions, views and beliefs of Revelation as of the date of this document. Such statements involve known and unknown risks and uncertainties, and undue reliance should not be placed thereon. Neither Revelation nor any of its affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein and nothing contained herein should be relied upon as a promise or representation as to past or future performance. Revelation and its members, partners, stockholders, managers, directors, officers, employees and agents do not have any obligation to update any information included herein. Certain information contained herein has been obtained from published and non-published sources and/or prepared by third-parties, and in certain cases has not been updated through the date hereof. While such information is believed to be reliable for the purposes of this document, Revelation assumes no responsibility for the accuracy or completeness of such information and such information has not been independently verified by it. The inclusion of any third-party firm and/or company names, brands and/or logos does not imply any affiliation with these firms or companies. None of these firms or companies have endorsed Revelation or any affiliated entities or personnel. Recipients of this document agree that none of Revelation or its affiliates or its or their respective partners, members, employees, officers, directors, agents, or representatives shall have any liability for any misstatement or omission of fact or any opinion expressed herein.

Certain information contained herein constitutes “forward-looking statements,” which can be identified by the use of terms such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “projects,” “future,” “targets,” “intends,” “plans,” “believes,” “estimates” (or the negatives thereof) or other variations thereon or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, some of which are beyond the control of Revelation. Actual results, performance, prospects or opportunities could differ materially from those expressed in or implied by the forward-looking statements. Additional risks of which Revelation is not currently aware also could cause actual results to differ. In light of these risks, uncertainties and assumptions, recipients should not place undue reliance on any forward-looking statements. The forward-looking events discussed in this document may not occur. Revelation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The delivery of this document at any time shall not under any circumstances create an implication that the information contained herein is correct as of any time after the earlier of the relevant date specified herein or the date of this document.

Any offer, sale or solicitation of interests in any private investment vehicle offered by Revelation in the future (each, a “Fund”) will be made only pursuant to such Fund’s confidential private placement memorandum (the “Memorandum”), limited partnership agreement and subscription agreement, and will be subject to the terms and conditions contained in such documents in accordance with applicable securities laws. This document is qualified in its entirety by reference to any such Fund’s Memorandum, including without limitation all of the cautionary statements and risk factors set forth therein, the applicable limited partnership agreement and the applicable subscription agreement related thereto, copies of all of which can be made available in the future to qualified investors upon request and should be read carefully prior to any investment in any such Fund.